Menu

Study: Vaping Causes DNA Damage in Human Cells and Mice

New findings suggest that nicotine inhaled from e-cigarettes could contribute to cancer and heart disease, but critics warn that the data are too preliminary to draw such conclusions.

Jan 31, 2018
Ashley Yeager

FLICKR, VAPING 360Nicotine inhaled from e-cigarettes can damage DNA in mouse heart, lung, and bladder and in cultured human lung and bladder cells, a new study shows. The results, published Monday (January 29) in PNAS, suggest that vaping increases the risk of developing cancer and heart disease and reinforce the research showing e-cigarettes’ risks to human health.

The DNA changes were similar to those linked to secondhand smoke, study coauthor Moon-shong Tang of New York University tells The Guardian. Specifically, the team found that two mutagenic compounds develop in lung, bladder, and heart cells exposed to e-cigarette smoke. DNA-repair activity and the repair proteins XPC and OGG1/2 were reduced in the lung tissue of mice.

See “Swapping Cigarettes for Vaping

Critics caution that the mice in the study were exposed to higher levels of e-cigarette smoke than those who vape might inhale (although Bloomberg reports that, over 12 weeks, mice were exposed to a dose similar to what a human would intake after smoking e-cigarettes lightly for 10 years). Still, “this study shows nothing at all about the dangers of vaping,” Peter Hajek, director of the Wolfson Institute of Preventive Medicine's Tobacco Dependence Research Unit at Queen Mary University of London, notes in The Guardian. “It doesn’t show that vaping causes cancer.”

In the paper, Tang and his colleagues concede that “it takes decades for carcinogen exposure to induce cancer in humans, [so] for decades to come there will be no meaningful epidemiological study to address the carcinogenicity of [e-cigarette smoke].” Still, the levels of carcinogenic compounds are higher in the blood of vapers than nonsmokers, pointing to the increased risk of developing cancer.

The bottom line, Tang tells Bloomberg, is: “Don’t think a vapor is harmless.”

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.